Blood Group Antibodies and Their Significance in Transfusion Medicine

Transfusion Medicine Reviews

Volumn 21, Issue 1, 2007, Pages 58-71

  Poole, Joyce ^a   Daniels, Geoff ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIBODY;

ALLOIMMUNIZATION; ANTIBODY DETECTION; ARTICLE; BLOOD COMPATIBILITY; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; ERYTHROCYTE TRANSFUSION; HEALTH PRACTITIONER; HUMAN; IMMUNOASSAY; INCIDENCE; MORBIDITY; MORTALITY; NEWBORN HEMOLYTIC DISEASE; NONHUMAN; QUESTIONNAIRE;

ABO BLOOD-GROUP SYSTEM; ANEMIA, HEMOLYTIC; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; FEMALE; FETAL DISEASES; FETOMATERNAL TRANSFUSION; HISTORY, 20TH CENTURY; HUMANS; INFANT, NEWBORN; ISOANTIBODIES; PREGNANCY;

EID: 33845303962     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2006.08.003     Document Type: Article

References (48)

1. Klein H.G., and Anstee D.J. Blood transfusion in clinical medicine. 11th ed. (2005), Blackwell Publishing, Oxford (UK)
2. Issitt P.D., and Anstee D.J. Applied blood group serology. 4th ed. (1998), Montgomery Scientific Publications, Durham (NC)
3. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 30 (1990) 583-590
4. Hadley A.G., and Turner C. Pathophysiology of the alloimmune cytopenias. In: Hadley A., and Soothill P. (Eds). Alloimmune disorders of pregnancy (2002), Cambridge University Press, Cambridge (UK) 1-20
5. Vaughan J.I., Warwick R., Letsky E., et al. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am. J. Obstet. Gynecol. 171 (1994) 247-252
6. Weiner C.P., and Widness J.A. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am. J. Obstet. Gynecol. 174 (1996) 547-551
7. Frohn C., Dümbgen L., Brand J.-M., et al. Probability of anti-D development in D- patients receiving D+ RBCs. Transfusion 43 (2003) 893-898
8. Redman M., Regan F., and Contreras M. A prospective study of the incidence of red cell alloimmunization following transfusion. Vox Sang. 71 (1996) 216-220
9. Olujohungbe A., Hambleton I., Stephens L., et al. Red cell antibodies in patients with homozygous sickle cell disease: A comparison of patients in Jamaica and the United Kingdom. Br. J. Haematol. 113 (2001) 661-665
10. Freidman D.F., Kim H.C., and Manno C.S. Hyper-hemoloysis associated with red cell transfusion in sickle cell disease. Transfusion 33 (1993) (Suppl. 14S)
11. Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion 37 (1997) 357-361
12. King K.E., Shirey R.S., Lankiewicz M.E., et al. Delayed hemolytic transfusion reactions in sickle cell disease: Simultaneous destruction of recipients' red cells. Transfusion 37 (1997) 376-381
13. Win N., Doughty H., Telfer P., et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion 41 (2001) 323-328
14. Petz L.D., Calhoun L., Shulman I.A., et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 37 (1997) 382-392
15. Chapman J.F., Elliott C., Knowles S.M., et al. Guidelines for compatibility procedures in blood transfusion laboratories. Working Party of the British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus. Med. 14 (2004) 59-73
16. Garratty G. Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Transfus. Med. Rev. 4 (1990) 297-312
17. Zupanska B., Brojer E., Richards Y., et al. Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn. Vox Sang. 56 (1989) 247-253
18. Nance S.J., Nelson J.M., Horenstein J., et al. Monocyte monolayer assay: An efficient noninvasive technique for predicting the severity of haemolytic disease of the new-born. Am. J. Clin. Pathol. 92 (1986) 89-92
19. Garner S.F., Gorick B.D., Lai W.Y.Y., et al. Prediction of the severity of haemolytic disease of the newborn. Vox Sang. 68 (1995) 169-176
20. Engelfreit C.P., and Ouwehand W.H. ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies. Ballieres Clin Hematol 3 (1990) 321-337
21. Urbaniak S.J., Greiss M.A., Crawford R.J., et al. Prediction of the outcome of rhesus haemolytic disease of the newborn: Additional information using an ADCC assay. Vox Sang. 46 (1984) 323-329
22. Hadley A.G., Wilkes A., Goodrick J., et al. The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn. Br. J. Obstet. Gynaecol. 105 (1998) 231-234
23. International Committee for Standardization in Hematology. Recommended methods for radioisotope red cell survival studies. Br. J. Haematol. 45 (1980) 659-666
24. Nance S.J., Arndt P., and Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 27 (1987) 449-452
25. Arndt P.A., and Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 44 (2004) 1273-1281
26. Daniels G., Poole J., de Silva M., et al. The clinical significance of blood group antibodies. Transfus. Med. 12 (2002) 287-295
27. Hadley A., Wilkes A., Poole J., et al. A chemiluminescence test for predicting the outcome of transfusing incompatible blood. Transfus. Med. 9 (1999) 337-342
28. Daniels G. Human blood groups. 2nd ed. (2002), Blackwell Science, Oxford (UK)
29. Hardman J.T., and Beck M.L. Hemagglutination in capillaries: correlation with blood group specificity and IgG subclass. Transfusion 21 (1981) 343-346
30. Pineda A.A., Vamvakas E.C., Gorden L.D., et al. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion 39 (1999) 1097-1103 (and corrections in Transfusion 2000;40:891)
31. Hoppe B., Pastucha L., Seltsam A., et al. Acute haemolytic transfusion reactions due to weak antibodies that in vitro did not seem to be clinically significant. Vox Sang. 82 (2002) 207-210
32. Nance S.T. Do HLA antibodies cause hemolytic transfusion reactions or decreased RBC survival? Editorial. Transfusion 43 (2004) 687-690
33. Benson K., Agosti S.J., Latoni-Benedetti G.E., et al. Acute and delayed hemolytic transfusion reactions secondary to HLA alloimmunization. Transfusion 43 (2003) 753-757
34. Takeuchi C., Ohto H., Miura S., et al. Delayed and acute hemolytic transfusion reactions resulting from red cell antibodies and red-cell reactive HLA antibodies. Transfusion 45 (2005) 1925-1929
35. Anstee D., Levene C., Mallory D., et al. Rare Blood. An ISBT Working Party Report on Rare Blood Donors. Vox Sang. 77 (1999) 58-62
36. Seltsam A., Wagner F.F., Salama A., et al. Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. Transfusion 43 (2003) 1563-1566
37. National Institute for Clinical Excellence. Technology appraisal guidance 41. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women (2002), NICE, London
38. Daniels G. Blood group antibodies in haemolytic disease of the fetus and newborn. In: Hadley A., and Soothill P. (Eds). Alloimmune disorders of pregnancy (2002), Cambridge University Press, Cambridge (UK) 21-40
39. Garner S.F., Devenish A., Barber H., et al. The importance of monitoring 'enzyme-only' red cell antibodies during pregnancy. Vox Sang. 61 (1991) 219-220
40. Caine M.E., and Mueller-Heubach E. Kell sensitization in pregnancy. Am. J. Obstet. Gynecol. 154 (1986) 85-90
41. Daniels G., Hadley A., and Green C.A. Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion 43 (2003) 115-116 (letter)
42. a and the potential clinical value of Duffy genotyping in pregnancies at risk. Transfus. Med. 7 (1997) 301-304
43. Arndt P.A., Garratty G., Daniels G., et al. Late onset neonatal anemia due to anti-Ge: possible association with destruction of erythroid progenitors. Transfus. Med. 15 (2005) 125-132
44. a-antibodies. Glycoconj. J. 9 (1992) 325-329
45. Le Masne A., Vachée A., Horbey C., et al. Forme sévère de maladie hémolytique néonatale par allo-immunisation anti-Vel. Arch. Fr. Pediatr. 49 (1992) 899-901
46. Daniels G., Finning K., Martin P., et al. Fetal blood group genotyping from DNA from maternal plasma: An important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang. 87 (2004) 225-232
47. van der Schoot C.E. Molecular diagnostics in immunohaematology. Vox Sang. 87 (2004) 189-192 (Suppl 2)
48. Anstee D.J. Goodbye to agglutination and all that?. Transfusion 45 (2005) 652-653